Apnimed screens with strong financial-strength characteristics and net insider buying, and ranks as a growth leader among industry peers, with a value profile that skews constructive on price-to-earnings. No current share price is available this run, so no trade setup or risk/reward can be computed.
Thesis pillars
- Strong Piotroski Financial Strength↓Deteriorating
- Net Bullish Insider Buying→Stable
- Industry Growth Leadership Rank↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Apnimed, Inc. (APMD) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $26.69, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2); Leverage penalty (D/E 1.2): -0.5.
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA)... Read more
Hold if already holding. Not a fresh buy at $26.69, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2); Leverage penalty (D/E 1.2): -0.5. Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 4.8/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 59d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-09-13Recent Developments — Apnimed, Inc.
Latest news
- NEWS APMD SWOT Analysis: Financial Resilience Amidst Challenges Revea - GuruFocus — GuruFocus neutral
- NEWS Apnimed (APMD) Insider Trading Activity 2026 - MarketBeat — MarketBeat neutral
- NEWS Apnimed Q2 Results: EPS beats estimates, sales at $12.08M - scanx.trade — scanx.trade positive
- NEWS Apnimed Q2FY26 Results: Net income turns positive at $125.9 million - scanx.trade — scanx.trade positive
- NEWS Apnimed (APMD) Earnings Date and Reports 2026 - MarketBeat — MarketBeat neutral
Generated 2026-09-14T05:21:57Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Revenue shrinking — -29.4% YoY. Growth thesis broken unless recovery story develops.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $26.69, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2); Leverage penalty (D/E 1.2): -0.5. Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $42.78 (+60.3%), stop $24.39 (−9.4%), A.R:R 4.2:1. Score 4.8/10, moderate confidence.
Take-profit target: $42.78 (+63.1% upside). Target $42.78 (+60.3%), stop $24.39 (−9.4%), A.R:R 4.2:1. Stop-loss: $24.39.
V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2); Leverage penalty (D/E 1.2): -0.5; Weak overall score: 4.8/10.
Apnimed, Inc. trades at a P/E of 4.6 (forward -6.6). TrendMatrix value score: 7.2/10. Verdict: Hold.
What does Apnimed, Inc. do?Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that...
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.